Jiayue Huang

Had a really nice chat with Affamed President Ji Li on topics including the outlook of China's biosimilar market. https://t.co/21E7Aucptn #S&P Global

ICYMI

Cindy Huang @cindyhuang_biz

April marks the 3rd anniversary of HK's biotech listing scheme. I talked to @HKEXGroup's Christina Bao today on the market outlook and the exchange's endeavor to attract more foreign companies to list. #biotech #ipo https://t.co/1cHLOXqyrl

#hkcovid Finally writing something about nasal spray vaccine - pretty sure I will go for it when it’s out! And hey, made by#hku. https://t.co/JyAd7A9ukg #S&P Global

April marks the 3rd anniversary of HK's biotech listing scheme. I talked to @HKEXGroup's Christina Bao today on the market outlook and the exchange's endeavor to attract more foreign companies to list. #biotech #ipo https://t.co/1cHLOXqyrl

#healthcare companies in APAC saw record investment from #PrivateEquity funds in 2020, and the best may be yet to come. Experts said we may see more and larger deals in Asia as investors ramp up and broaden their search. https://t.co/8MDs6Y73tO

A same trend we have seen with Apple, Google..

Market Intelligence: Healthcare @SPGMIHealthcare

JD Health is aiming to beef up its medical device business through both in-house development and potential investment targets, @cindyhuang_biz reports https://t.co/Qvm2Pzjux3 https://t.co/LKabldTAra

One step forward on #Takeda's cell and #genethreapy journey. #Healthcare #GeneTherapy #CART

Market Intelligence: Healthcare @SPGMIHealthcare

Takeda's latest alliance with Germany's Evotec reflects the "tremendous promise" of RNA technology, the Japanese company told @cindyhuang_biz https://t.co/1x77RQeYJ4 https://t.co/NtWmeRPsjO

Good morning from HK- and ICYMI

Cindy Huang @cindyhuang_biz

Had a nice chat with #JDHealth’s Dongyuan Wang on China’s online medical consultation businesses. #AI and #remotehealthcare are really changing the landscape of healthcare, can’t wait to see how the industry evolves. #AI #healthcare https://t.co/tCP5BuliYW

Had a nice chat with #JDHealth’s Dongyuan Wang on China’s online medical consultation businesses. #AI and #remotehealthcare are really changing the landscape of healthcare, can’t wait to see how the industry evolves. #AI #healthcare https://t.co/tCP5BuliYW

ICYMI #vaccine #CovidVaccine #Chinabiotech

Cindy Huang @cindyhuang_biz

Investors are putting money into China's vaccine industry amid the pandemic, shaking off the scandals that once shadowed the country's vaccine industry. According to one of the experts, the fund raised by Chinese vaccine companies can quadruple from 2017. https://t.co/6ZMRiJrt2A

Investors are putting money into China's vaccine industry amid the pandemic, shaking off the scandals that once shadowed the country's vaccine industry. According to one of the experts, the fund raised by Chinese vaccine companies can quadruple from 2017. https://t.co/6ZMRiJrt2A

ICYMI: The licensing landscape of #chinabiotech

Cindy Huang @cindyhuang_biz

Chinese companies are stepping up licensing drugs to overseas companies, mostly "me too" and "me better" (or fast followers) for now. Experts said the trend of "from China to global" will continue, and potentially we will see more innovative #drugs in the future.#biotech

Chinese companies are stepping up licensing drugs to overseas companies, mostly "me too" and "me better" (or fast followers) for now. Experts said the trend of "from China to global" will continue, and potentially we will see more innovative #drugs in the future.#biotech

Market Intelligence: Healthcare @SPGMIHealthcare

Chinese drugmakers are increasingly licensing homegrown therapies to overseas companies, tweaking popular treatments to make them more cost-effective, @cindyhuang_biz reports https://t.co/OOqDkvMUfy https://t.co/aZ8x1iozwR

Had a nice chat with Union Medical's Levin Lee. If you are still curious about how private clinics will expand in mainland China with the existing hurdle, here's your answer. https://t.co/ydI1m6uy2c

ICYMI: "People will be pickier and more actively seeking products that they want instead of passively waiting for products divested by others," said Ronnie Ede, CFO of Innovent Biologics. #BiotechNews #China #Pharmaceutical #licensing

Market Intelligence: Healthcare @SPGMIHealthcare

Early-stage biotech companies are leading the trend of Chinese drugmakers beefing up their product pipelines through overseas licensing deals, @cindyhuang_biz reports FULL ANALYIS: https://t.co/4mfaEZNtuH https://t.co/r8XWNn6CrP

Chinese drugmakers are still in buying mode but may be pickier as the market becomes more mature and sophisticated. Check my latest to see how the ecosystem has been evolving in the past years and what these companies want to buy in the future. https://t.co/ZqPQEEzw0Y

Chinese PD-1 drugmakers are paving the way to sell their drugs overseas with trials in the U.S. I talked to Junshi co-founder Yao Sheng and other experts about the drivers behind the expansion, click for the details. #pd1 #cancer #chinabiotech https://t.co/vgeLKBXxQy